GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » LT-Debt-to-Total-Asset

BIOYF (Biosyent) LT-Debt-to-Total-Asset : 0.02 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biosyent's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.02.

Biosyent's long-term debt to total assets ratio declined from Sep. 2023 (0.03) to Sep. 2024 (0.02). It may suggest that Biosyent is progressively becoming less dependent on debt to grow their business.


Biosyent LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biosyent's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent LT-Debt-to-Total-Asset Chart

Biosyent Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.04 0.03 0.03 -

Biosyent Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.02 -

Biosyent LT-Debt-to-Total-Asset Calculation

Biosyent's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.774/30.955
=0.03

Biosyent's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.659/33.568
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Biosyent LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biosyent's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Biosyent Headlines

From GuruFocus

Q2 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

BioSyent Declares First Quarter 2025 Dividend

By GlobeNewswire 01-30-2025

Q4 2020 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

Q2 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2022 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

BioSyent to Attend Planet MicroCap Showcase

By GlobeNewswire 04-23-2024

Q4 2018 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024